Allergan introduces Juvéderm VOLUX

05 Apr 2019

Global pharmaceutical company Allergan has launched Juvéderm VOLUX, a hyaluronic acid injectable gel that uses the existing VYCROSS patented technology.

The product is design to be used to sculpt the chin and jaw area, giving facial definition that can last for up to 24 months, the company claims.

In a clinical trial where the primary goal was to evaluate the mean change in facial angle from baseline compared with a control group, 94% of patients (85) reported that they were satisfied with the results three months’ post-treatment. At 18 months, 62% of patients (79) still felt results were positive. This product also contains lidocaine to aid with comfortable treatment experience, Allergan explains.

Marc Princen, executive vice president and president, international commercial for Allergan said, "Juvéderm has been answering the needs of consumers for well over a decade, helping them to achieve their desired look. As the global leader in medical aesthetics we're constantly looking to evolve our portfolio of products and technologies, and now, with Juvéderm VOLUX, men and women around the world can achieve the defined and contoured lower face that they're looking for – allowing them to ‘Sculpt’ it!"

The Juvéderm VOLUX is also CE marked to restore and create volume in the chin and jaw area.

Comments

Log-in to post a comment